Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 12;36(14):e89.
doi: 10.3346/jkms.2021.36.e89.

Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea

HeeKyoung Choi  1   2 , Gi Hyeon Seo  3
Affiliations

Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea

HeeKyoung Choi et al. J Korean Med Sci. .

Abstract

Background: The occurrence of hepatocellular carcinoma (HCC) is a major concern during antiviral therapy for chronic hepatitis B. There are conflicting opinions regarding the effects of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on HCC prevention. We assessed these two antiviral medications for preventing HCC in treatment-naïve patients with chronic hepatitis B.

Methods: We conducted a retrospective cohort study using nationwide claims data from the Korea Health Insurance Review and Assessment Service. We included 55,473 treatment-naïve adult cases where ETV or TDF treatment was started between 2013 and 2017 (cohort 1). The ETV and TDF groups were matched 1:2 based on age, sex, comorbidities, hospital type, and index date year. Patients were followed up until December 2018. The outcome was the development of HCC. Subgroup analyses were conducted according to sex, age, hospital type and the presence of cirrhosis. We also compared the outcomes of patients who had started antiviral therapy during the 2012-2014 period (cohort 2).

Results: The matched participants (18,491 in the ETV and 36,982 in the TDF groups) were a part of the study for, on average, 41.2 months. The incidence of HCC did not differ significantly between the ETV (1.46 per 100 patient-years) and the TDF (1.36 per 100 patient-years) treatments (hazard ratio, 0.93; 95% confidence interval, 0.86-1.01; P = 0.081). By contrast, HCC incidence was significantly higher in the ETV group than tenofovir group of cohort 2.

Conclusion: In patients with chronic hepatitis B, the ETV treatment did not result in a higher rate of HCC than the TDF treatment.

Keywords: Entecavir; Hepatitis B; Hepatocellular Carcinoma; Tenofovir.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Flow diagram of the study population in matched set.
ETV = entecavir, TDF = tenofovir disoproxil fumarate, COPD = chronic obstructive pulmonary disease.
Fig. 2
Fig. 2. Cumulative incidence of hepatocellular carcinoma in matched sets treated with entecavir or tenofovir. Event rates were based on Kaplan-Meier estimates.
HCC = hepatocellular carcinoma, TDF = tenofovir disoproxil fumarate, ETV = entecavir.
Fig. 3
Fig. 3. Cumulative incidence of hepatocellular carcinoma in the 2012–2014 cohort matched sets treated with entecavir or tenofovir. Event rates were based on Kaplan-Meier estimates.
HCC = hepatocellular carcinoma, TDF = tenofovir disoproxil fumarate, ETV = entecavir.
See this image and copyright information in PMC

References

    1. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HL, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. - PubMed
    1. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. - PMC - PubMed
    1. Terrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. - PMC - PubMed
    1. Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol. 2019;5(1):30–36. - PMC - PubMed
    1. Kim SU, Seo YS, Lee HA, Kim MN, Lee YR, Lee HW, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. J Hepatol. 2019;71(3):456–464. - PubMed

MeSH terms

Grants and funding